drugset / Trial / NCT06619847

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

NCT06619847

Phase 2 Completed 367 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectomy.

Timeline

Start
2024-10-29
Primary completion
2025-05-27
Completion
2025-05-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule Oral
Comparator Hydrocodone Unknown Oral
Subject VX-993 Unknown Oral

Indications

No indication recorded.